Abcellera Stock Based Compensation from 2010 to 2026
| ABCL Stock | USD 3.54 0.09 2.48% |
Stock Based Compensation | First Reported 2019-03-31 | Previous Quarter 13.9 M | Current Value 12.9 M | Quarterly Volatility 6.4 M |
Check Abcellera Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abcellera Biologics' main balance sheet or income statement drivers, such as Net Interest Income of 46.5 M, Interest Income of 46.5 M or Depreciation And Amortization of 26.5 M, as well as many indicators such as Price To Sales Ratio of 12.92, Dividend Yield of 0.0 or PTB Ratio of 0.85. Abcellera financial statements analysis is a perfect complement when working with Abcellera Biologics Valuation or Volatility modules.
Abcellera | Stock Based Compensation | Build AI portfolio with Abcellera Stock |
Historical Stock Based Compensation data for Abcellera Biologics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Abcellera Biologics represents a compelling investment opportunity.
Latest Abcellera Biologics' Stock Based Compensation Growth Pattern
Below is the plot of the Stock Based Compensation of Abcellera Biologics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Abcellera Biologics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Abcellera Biologics' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation | 10 Years Trend |
|
Stock Based Compensation |
| Timeline |
Abcellera Stock Based Compensation Regression Statistics
| Arithmetic Mean | 18,863,114 | |
| Geometric Mean | 3,439,173 | |
| Coefficient Of Variation | 136.90 | |
| Mean Deviation | 22,667,324 | |
| Median | 615,000 | |
| Standard Deviation | 25,823,378 | |
| Sample Variance | 666.8T | |
| Range | 67M | |
| R-Value | 0.82 | |
| Mean Square Error | 234.8T | |
| R-Squared | 0.67 | |
| Significance | 0.000059 | |
| Slope | 4,185,526 | |
| Total Sum of Squares | 10669.6T |
Abcellera Stock Based Compensation History
Other Fundumenentals of Abcellera Biologics
Abcellera Biologics Stock Based Compensation component correlations
Click cells to compare fundamentals
About Abcellera Biologics Financial Statements
Abcellera Biologics investors utilize fundamental indicators, such as Stock Based Compensation, to predict how Abcellera Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation | 55.8 M | 38.2 M | |
| Stock Based Compensation To Revenue | 0.74 | 0.51 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Abcellera Biologics Correlation against competitors. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Abcellera Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.459 | Earnings Share (0.49) | Revenue Per Share | Quarterly Revenue Growth 7.882 | Return On Assets |
Understanding Abcellera Biologics requires distinguishing between market price and book value, where the latter reflects Abcellera's accounting equity. The concept of intrinsic value - what Abcellera Biologics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Abcellera Biologics' price substantially above or below its fundamental value.
Understanding that Abcellera Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abcellera Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Abcellera Biologics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.